Trial · NCT06055621
Evaluation of DASATINIB Monotherapy Efficacy in Acute Myeloid Leukemia Patients Refractory to VENETOCLAX-AZACITIDINE
NCT06055621, Phase 2, Suspended, Institut Paoli-Calmettes
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Evaluation of DASATINIB Monotherapy Efficacy in Acute Myeloid Leukemia Patients Refractory to VENETOCLAX-AZACITIDINE. Trials, record NCT06055621. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT06055621
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Evaluation of DASATINIB Monotherapy Efficacy in Acute Myeloid Leukemia Patients Refractory to VENETOCLAX-AZACITIDINE
- NCT number
- NCT06055621
- Status
- Suspended
- Phases
- Phase 2
- Enrollment
- 35 participants, estimated
- Lead sponsor
- Institut Paoli-Calmettes
- Conditions
- Acute Myeloid Leukemia
- Interventions
- Dasatinib
- First posted
- 2023-09-28
- Last updated
- 2026-10-01
Source ClinicalTrials.gov
Registered outcomes7
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | tumor response | 2 months | Objective response rate after 2 cycles of 28 days DASATINIB defined as the rate of complete remission (CR) or complete remission with incomplete hematologic recovery (CRi) according to ELN 2022 criteria. |
| Secondary | response rates | 3 months | Different response rates (RC, CRi, or partial remission (PR)) according to ELN 2022 criteria. |
| Secondary | Time to response | 3 months | Time to response (time between the start of the treatment until achievement of the CR, CRi or PR) |
| Secondary | Duration of relapse-free period | 3 months | Duration of relapse-free period (time between the response time and the relapse) |
| Secondary | Event-free survival | 3 months | Event-free survival (EFS, time between start of treatment and relapse, no response or death) |
| Secondary | Overall survival | 3 months | Overall survival (duration of survival from the start of the treatment) |
| Secondary | Occurrence of Adverse Events | 3 months | Occurrence of Adverse Events according to CTCAE v5.0 and Serious Adverse Reaction |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT06055621
GET https://conductscience.org/api/trials/v1/NCT06055621/registered